MA-STILLA-TECHNOLOGIES
30.6.2021 12:02:11 CEST | Business Wire | Press release
Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and clinical diagnostics, today announced the appointment of Matthew Grow, PhD, to Vice President of Global Marketing and Commercial Operations. Trained as a molecular biologist, Dr. Grow brings over 25 years of experience in biological research and commercial management to Stilla during a time of dynamic growth for the company and for digital PCR , which is transforming the fields of genomics and genetic analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005367/en/
“We are thrilled to welcome Matt on board as Stilla looks to become a mainstay force across the global genomics research and genetic testing markets,” said Philippe Mourere, President and CEO, Stilla Technologies. “His solid track record of commercializing multiplex platforms and building core commercial teams will serve Stilla well as we enter our next phase of development.”
Dr. Grow joins Stilla Technologies from Abcam where he led the successful launch and growth of the company’s portfolio of proteomic and genomic multiplex platforms and assays. Prior to that he served at Wuxi NextCODE (now Genuity Science) where he oversaw marketing of the company’s suite of population-scale genomic analysis software. Previously he served at Luminex Corporation where he developed and managed strategic marketing for their pipeline of protein and molecular instruments and consumables. He holds a Ph.D. in Molecular Biology and completed his Postdoctoral Fellowship at Harvard University.
“I’m excited to join Stilla and work with an incredible leadership team who are committed to making products that scientists need to accelerate breakthrough discoveries,” said Dr. Grow. “Stilla’s Crystal Digital PCR™ features an easy workflow, higher levels of multiplexing, and intuitive software which will democratize digital PCR as a mainstream platform for any researcher or clinician.”
About Stilla Technologies
Stilla Technologies is the global life sciences company providing a groundbreaking Crystal Digital PCR™ (dPCR) solution that enables researchers and clinicians to accelerate development of advanced genetic testing and molecular biology assays for a wide range of applications, including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and GMO and environmental testing. Stilla aims to make dPCR a lab commodity for life sciences research and molecular diagnostics with its flexible naica® system, which incorporates proprietary, cutting–edge microfluidic innovations in addition to unsurpassed customer service and application support. With U.S. headquarters in Boston and European headquarters in Paris, Stilla’s dPCR technology is employed by leading academic research institutions and pharmaceutical companies across the globe. To learn more visit www.stillatechnologies.com and connect with Stilla on social media Twitter , LinkedIn and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005367/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom